Stereotaxis (STXS) Net Income towards Common Stockholders (2010 - 2026)
Stereotaxis (STXS) reported Net Income towards Common Stockholders of -$6.2 million for Q1 2026, down 0.57% year-over-year from -$6.2 million in Q1 2025, and down 5.52% quarter-over-quarter from -$5.8 million in Q4 2025.
Stereotaxis (STXS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$6.2 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$6.2 million, down 0.57% year-over-year; the trailing twelve-month figure through Mar 2026 was -$23.0 million (up 13.89% YoY), and the FY2025 annual result was -$22.9 million, up 9.62% from the prior year.
- Net Income towards Common Stockholders declined to -$6.2 million in Q1 2026 per STXS's latest filing, from -$5.8 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$4.1 million in Q2 2025 and troughed at -$7.8 million in Q4 2024.
- A 5-year average of -$5.7 million and a median of -$5.7 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders slumped 253.75% in 2022, then surged 32.71% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$4.5 million in 2022, then retreated by 19.75% to -$5.4 million in 2023, then sank by 45.73% to -$7.8 million in 2024, then grew by 25.39% to -$5.8 million in 2025, then dropped by 5.52% to -$6.2 million in 2026.
- Business Quant data shows STXS's Net Income towards Common Stockholders at -$6.2 million in Q1 2026, -$5.8 million in Q4 2025, and -$6.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 826.00 Mn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -274.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 239.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 398.73 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 135.40 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 13.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -77.90 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 112.77 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 2.00 Mn |
| 10 | Stereotaxis | 180.48 Mn | 165.86 Mn | 3.79 Mn | -6.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.17 Mn |
| Dec 31, 2025 | -5.85 Mn |
| Sep 30, 2025 | -6.79 Mn |
| Jun 30, 2025 | -4.14 Mn |
| Mar 31, 2025 | -6.14 Mn |
| Dec 31, 2024 | -7.84 Mn |
| Sep 30, 2024 | -6.52 Mn |
| Jun 30, 2024 | -6.16 Mn |
| Mar 31, 2024 | -4.84 Mn |
| Dec 31, 2023 | -5.38 Mn |
| Sep 30, 2023 | -5.71 Mn |
| Jun 30, 2023 | -5.29 Mn |
| Mar 31, 2023 | -5.68 Mn |
| Dec 31, 2022 | -4.49 Mn |
| Sep 30, 2022 | -5.26 Mn |
| Jun 30, 2022 | -5.47 Mn |
| Mar 31, 2022 | -4.42 Mn |
| Dec 31, 2021 | -3.69 Mn |
| Sep 30, 2021 | -4.96 Mn |
| Jun 30, 2021 | -1.55 Mn |